Four research teams have independently identified a RET kinase fusion that could drive about 2% of lung adenocarcinoma cases. One of the groups hopes to begin a Phase II trial of Pfizer's multikinase inhibitor Sutent in RET fusion-positive patients in 1H12. In addition, Xcovery is looking for more specific RET inhibitors.